Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MorphoSys has reached a milestone in ophthalmology program for the development of HuCAL-derived, fully human antibody, with Novartis.
Subscribe to our email newsletter
Novartis made a milestone payment related to clinical trial application (CTA/IND) and projected initiation of a Phase 1 trial.
MorphoSys chief scientific officer Dr. Marlies Sproll said the milestone is the first up to five clinical milestones expected from collaborators during the course of the year.
"In total, our collaboration with Novartis has resulted in seven clinical programs to date, three currently being in Phase 1 and four in Phase 2," Sproll added.